HCM News & Events

Hutchmed (HCM) reported that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib and osimertinib combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor therapy. Savolitinib is an oral, potent and highly selective MET TKI being jointly developed by AstraZeneca (AZN) and Hutchmed and commercialized by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI. Based on interim data from SACHI, the savolitinib and osimertinib combination was granted regulatory approval in China in June 2025.

Hutchmed announced that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib, a novel spleen tyrosine kinase inhibitor, in adult patients with warm antibody autoimmune hemolytic anemia in China has met its primary endpoint of durable hemoglobin response rate within weeks 5 to 24 of treatment. Autoimmune hemolytic anemia is an autoimmune disorder characterized by the destruction of red blood cells due to the production of antibodies against RBC. The incidence of AIHA is estimated to be 0.8-3.0/100,000 adults per year with an estimated prevalence of 17 per 100,000 adults and a death rate of 8-11%. wAIHA is the most common form of AIHA, accounting for about 75-80% of all adult AIHA cases.

Hutchmed announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, PDAC, in China. The first patient received the first dose on December 30, 2025.